[1] [1] LEE IT, NACHBAGAUER R, ENSZ D, et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine(mRNA-1010)in healthy adults: interim analysis［J］. Nature Communications, 2023, 14(1): 3631.

[2] [2] KIYONO H, FUKUYAMA S. NALT- versus Peyer’s-patch-mediated mucosal immunity ［J］. Nature Reviews Immunology, 2004, 4(9): 699-710.

[3] [3] HIDALGO A, CRUZ A, PEREZ-GIL J. Pulmonary surfactant and nanocarriers: toxicity versus combined nanomedical applications ［J］. Biochimica Et Biophysica Acta-biomembranes, 2017, 1859(9): 1740-1748.

[4] [4] WANG J, LI P, YU Y, et al. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity ［J］. Science, 2020, 367(6480): eaau0810.

[5] [5] CHENG X B, YU P, ZHOU X, et al. Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation: a new platform for synergistic oncology therapy ［J］. Acta Pharmaceutica Sinica B, 2022, 12(2): 924-938.

[6] [6] ENOSI TUIPULOTU D, NETZLER N E, LUN J H, et al. TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation ［J］. Antimicrobial Agents and Chemotherapy, 2018, 62(5): e02417-17.

[7] [7] SHEN Y, ZENG M, QIU F, et al. Resiquimod(R848)has more stronger immune adjuvantivity than other tested TLR agonists ［J］. Chinese Journal of Cellular and Molecular Immunology, 2017, 33(5): 591-596.

[8] [8] ZHOU J, NOURI-SHIRAZI M, TANG H, et al. R848/TLR7-mediated stronger CD8+T immunity is dependent on DC-NK cell interactions［J］. International Archives of Allergy And Immunologyl, 2022, 183(8): 860-875.

[9] [9] VAN AALST S, JANSEN M A A, LUDWIG I S, et al. Routing dependent immune responses after experimental R848-adjuvated vaccination ［J］. Vaccine, 2018, 36(11): 1405-1413.

[10] [10] VATTI A, MONSALVE D M, PACHECO Y, et al. Original antigenic sin: a comprehensive review ［J］. Journal of Autoimmunity, 2017, 83: 12-21.

[11] [11] HOLBROOK B C, AYCOCK S T, MACHIELE E, et al. An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates ［J］. Immunology, 2018, 153(3): 357-367.

[12] [12] HOLBROOK B C, D’AGOSTINO R B, TYLER AYCOCK S, et al. Adjuvanting an inactivated influenza vaccine with conjugated R848 improves the level of antibody present at 6months in a nonhuman primate neonate model ［J］. Vaccine, 2017, 35(45): 6137-6142.

[13] [13] CLEMENS E A, HOLBROOK B C, KANEKIYO M, et al. An R848-conjugated influenza virus vaccine elicits robust immunoglobulin G to hemagglutinin stem in a newborn nonhuman primate model ［J］.?Journal of Infectious Diseases, 2021, 224(2): 351-359.

[14] [14] CROFTS K F, HOLBROOK B C, D’AGOSTINO R B JR, et al. Analysis of R848 as an adjuvant to improve inactivated influenza vaccine immunogenicity in elderly nonhuman primates［J］. Vaccines(Basel), 2022, 10(4): 494.

[15] [15] CORTEZ A, LI Y, MILLER A T, et al. Incorporation of phosphonate into benzonaphthyridine Toll-like receptor 7 agonists for adsorption to aluminum hydroxide［J］.?Journal of Medicinal Chemistry, 2016, 59(12): 5868-5878.

[16] [16] DOWLING D J. Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants［J］. Immunohorizons, 2018, 2(6): 185-197.

[17] [17] DOWLING D J, SCOTT E A, SCHEID A, et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses［J］. Journal of Allergy and Clinical Immunology, 2017, 140(5): 1339-1350.

[18] [18] MIZUNO D, KIMOTO T, SAKAI S, et al. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys ［J］. Vaccine, 2016, 34(16): 1881-1888.

[19] [19] FOTOUHI F, SHAFFIFAR M, FARAHMAND B, et al. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus ［J］. Archives of Virology, 2017, 162(5): 1251-1260.